March 18, 2021. T-CURX completes successful scientific advice meeting with Geman Paul-Ehrlich-Institute for T-CURX CAR-T cell program in Acute Myeloid Leukemia

Scientific Advice Meeting with the German Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich Institute (PEI), resulted in a positive assessment and a confirmation of T-CURX strategy to advance T-CURX AML-CAR-T cell program to FiH clinical trials

Today, T-CURX accounces that the company has successfully completed a scientific advice meeting with assessors of the Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich Institute (PEI), Langen, Germany, in which the non-clinical data package and T-CURX plans for First-in-Human clinical trials of T-CURX CAR-T cell pipeline program for patients with Acute Myeloid Leukemia (AML) has been presented.

The assessors from PEI including experts for non-clinical development, safety, clinical and manufacturing (chemistry, manufacturing and controls, CMC) have essentially agreed with the clinical-trial-enabling development strategy of T-CURX to advance this CAR-T cell product candidate to First-in-Human clinical trials in AML patients, pending some final non-clinical evaluations.

The scientific advice meeting at PEI has therefore cleared T-CURX' strategy for the initiation of FiH clincial trials for T-CURX 2nd CAR-T cell therapy pipeline program in AML.